9 results about "Interferon alpha" patented technology

Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and / or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

A composition and a new method of manufacturing and producing such composition including modified interferon alpha 2 b, modified acetylated interferon alpha 2 b, and / or a mixture thereof is disclosed herein.

The invention relates to the technical field of medicines, and particularly discloses application of interferon alpha combined with stiripentanol in virus infection resistance. As an antiviral drug, interferon alpha has the problems of limited curative effect, remarkable side effect, narrow applicable crowd, inconvenience in medication and the like clinically. The invention finds that the accumulation of host lactic acid in the later stage of virus infection is a key negative factor, and lactic acid directly inhibits the antiviral activity of interferon alpha and induces inflammatory storm. Through combined use of a lactic dehydrogenase inhibitor stiripentol (Stiripentol, STP), lactic acid production is reduced, a lactic acid-mediated antiviral inhibition-inflammation promotion effect is reversed, and the antiviral activity of interferon alpha is enhanced and side effects are reduced. Experiments prove that the combined therapy can effectively inhibit virus replication and inflammatory factor expression, and a new strategy is provided for broad-spectrum antiviral therapy.

A composition and a new method of manufacturing and producing such composition including modified interferon alpha 2 b with deamidated amino acids is disclosed herein.

This invention relates to use of interferon-polymer conjugates described in the specification to treat idiopathic myelofibrosis, polycythaemia vera and essential thrombocythaemia.

A composition and a new method of manufacturing and producing such composition including modified interferon alpha 2 b with modified Nle substituted, Gly at position 45 substituted to Asp and / or Asn at position 66 substituted to Lys substituted modified interferon alpha 2 b, and / or a mixture thereof is disclosed herein.

The application discloses application of a probiotic preparation in vaginal flora regulation and anti-HPV, and relates to the technical field of biological medicine; a pharmaceutical composition for assisting in treating high-risk human papilloma virus infection, the pharmaceutical composition comprising: interferon, which is recombinant human interferon alpha-2b; and a vaginal probiotic preparation, which comprises an effective dose of lactobacillus live bacteria; wherein the interferon and the probiotic preparation are formulated into a combined preparation or separate preparations for vaginal administration. The application discloses a new mechanism that the probiotic activates specific immune pathways to synergistically resist viruses, and proves excellent curative effects of the combined therapy; in traditional cognition, the probiotic mainly restores flora balance through occupying competition and acid production.

A composition and a new method of manufacturing and producing such composition including modified interferon alpha 2 b with deamidated amino acids is disclosed herein.

A composition and a new method of manufacturing and producing such composition including modified interferon alpha 2 b, modified acetylated interferon alpha 2 b, and / or a mixture thereof is disclosed herein.